Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne

JAMA Dermatology

Volumn 151, Issue 9, 2015, Pages 941-944

  Plovanich, Molly ^a   YuWeng, Qing ^a   Mostaghimi, Arash ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ACNE; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WOMEN'S HEALTH; ACNE VULGARIS; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; MIDDLE AGED; PHYSIOLOGIC MONITORING; PREVALENCE; RISK FACTOR; UNITED STATES; UTILIZATION; YOUNG ADULT;

ACNE VULGARIS; ADOLESCENT; ADULT; FEMALE; HUMANS; HYPERKALEMIA; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MONITORING, PHYSIOLOGIC; POTASSIUM; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPIRONOLACTONE; UNITED STATES; YOUNG ADULT;

EID: 84941286885     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.34     Document Type: Conference Paper

References (16)

1. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984; 111(2):209-214.
2. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112(1):124-125.
3. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115(2): 227-232.
4. Shaw JC. Spironolactone in dermatologic therapy. J AmAcad Dermatol. 1991;24(2, pt 1):236-243.
5. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.
6. Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19 (2):163-166.
7. Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg. 2006;30(6):689-694.
8. Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J AmAcad Dermatol. 2008;58(1):60-62.
9. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43(3):498-502.
10. Weng QY, Plovanich M, Mostaghimi A. Potassium monitoring is not indicated for healthy young female patients on spironolactone for acne. Paper presented at: 73rd Annual Meeting of the American Academy of Dermatology; March 23, 2015; San Francisco, CA.
11. Al-Shohaib S, Shaker DS, Ghaedi BB, Alyarim M, Emara S, Behairy M. The hematopoietic effect of Epotin (recombinant human erythropoietin-α) on maintenance hemodialysis end-stage kidney disease patients. Transplant Proc. 2010;42(3):753-759.
12. Cummings BM, Macklin EA, Yager PH, Sharma A, Noviski N. Potassium abnormalities in a pediatric intensive care unit: frequency and severity. J Intensive Care Med. 2014;29(5):269-274.
13. Target Pharmacy. $4 and $10 Generic medication list. 2011. http://tgtfiles.target.com /pharmacy/WCMP02-030049-RxGenerics-NM9 .pdf. Accessed November 6, 2014.
14. Wal-Mart Stores, Inc. Retail prescription program drug list. 2013. http://i.walmart.com/i/if /hmp/fusion/genericdruglist.pdf. Accessed November 6, 2014.
15. BI-LO/Winn Dixie. Prescription drug plan. 2014. http://www.bi-lo.com/waystosave/Images1 /PDPDrugPriceList.pdf. Accessed November 6, 2014.
16. Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2014. http://www .cms.gov/Medicare/Medicare-Fee-for-Service -Payment/ClinicalLabFeeSched/clinlab.html. Accessed September 15, 2014.